Saurabh Saha - 01 Feb 2025 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Executive Officer, Director
Signature: /s/ Gregory Weinhoff, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 01 Feb 2025
Net transactions value: -$734,007
Form type: 4
Filing time: 04 Feb 2025, 16:56:32 UTC
Previous filing: 22 Jan 2025
Next filing: 20 Feb 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Tax liability	$734,007	-43,381	-10%	$16.92	386,017	01 Feb 2025	Direct	F1, F2
holding	CNTA	Ordinary Shares						38,000	01 Feb 2025	By trust	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTA	Share Option (right to buy)	Award	$0	+900,000		$0.000000	900,000	03 Feb 2025	Ordinary Shares	900,000	$16.90	Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F3	These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.
F4	1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 3, 2025.